In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts, and incremental regulatory shifts began to...
On 4 December 2025, London’s Conway Hall will host the third PSYCH Symposium, bringing together leaders across science, policy, investment and clinical medicine to chart the...
This article was submitted by Lucy da Silva, Psychedelic Support Therapist and CEO Silva Wellness, as part of Psychedelic Health’s op-ed program.
Ambio Life Sciences, a company known for its physician-led ibogaine therapy programmes, has been thrust into the global spotlight with the release of In Waves and...
A newly published systematic review titled on psilocybin’s effects on obsessive‑compulsive behaviours provides an up-to-date synthesis of research into the compound’s potential for treating OCD and...
Last week, the U.S.
Arcadia Medicine, a San Francisco-based biotech startup developing MDMA-like empathogens, this month closed roughly $9.25 million in seed financing and won FDA clearance to begin human...
Dr. Celia Morgan is one of the UK’s leading figures in ketamine and psychedelic research, especially in the domain of addiction and mental health.
For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment.
Professor David Nutt stands out as a leading figure in modern psychedelic science, tirelessly pushing the boundaries of how drugs such as psilocybin, MDMA, LSD, DMT,...
On Friday, the Royal College of Psychiatrists has published a new report assessing the safety and efficacy of psychedelics and related substances as treatments for mental...
Psychedelic medicine took a major step forward this month as JAMA published results from the first randomized, placebo-controlled trial of LSD for anxiety.
